Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
DR3DQ2 haplotype
GAD-alum
autoantigen
immunotherapy
intra-lymphatic treatment
lymph node
type 1 diabetes
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
30
11
2022
accepted:
24
01
2023
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
3
3
2023
Statut:
epublish
Résumé
GAD-alum given into lymph nodes to Type 1 diabetes (T1D) patients participating in a multicenter, randomized, placebo-controlled double-blind study seemed to have a positive effect for patients with DR3DQ2 haplotype, who showed better preservation of C-peptide than the placebo group. Here we compared the immunomodulatory effect of GAD-alum administered into lymph nodes of patients with T1D versus placebo with focus on patients with DR3DQ2 haplotype. GAD autoantibodies, GADA subclasses, GAD Higher GADA, GADA subclasses, GAD Patients with DR3DQ2 haplotype had a distinct early cellular immune response to GAD-alum injections into the lymph node, and predominant GAD
Identifiants
pubmed: 36817467
doi: 10.3389/fimmu.2023.1112570
pmc: PMC9933867
doi:
Substances chimiques
aluminum sulfate
34S289N54E
C-Peptide
0
Cytokines
0
Glutamate Decarboxylase
EC 4.1.1.15
Interleukin-10
130068-27-8
Interleukin-13
0
Interleukin-5
0
HLA Antigens
0
Banques de données
ClinicalTrials.gov
['NCT03345004']
Types de publication
Randomized Controlled Trial
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1112570Informations de copyright
Copyright © 2023 Puente-Marin, Dietrich, Achenbach, Barcenilla, Ludvigsson and Casas.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2012 May 1;188(9):4644-53
pubmed: 22461703
Lancet. 2011 Jul 23;378(9788):319-27
pubmed: 21714999
Diabetologia. 2020 Jun;63(6):1186-1198
pubmed: 32248243
Diabetes Care. 2008 Oct;31(10):1966-71
pubmed: 18628574
Diabetologia. 2013 Feb;56(2):391-400
pubmed: 23086558
Lancet. 2008 Nov 15;372(9651):1746-55
pubmed: 18814906
J Immunol. 2002 Apr 15;168(8):3707-11
pubmed: 11937520
J Immunol. 2011 Aug 15;187(4):1998-2005
pubmed: 21775681
Sci Transl Med. 2013 Jun 26;5(191):191ra82
pubmed: 23803704
Front Immunol. 2017 Jan 19;8:20
pubmed: 28154568
PLoS One. 2011;6(12):e29008
pubmed: 22174945
Lancet Diabetes Endocrinol. 2019 Jan;7(1):65-74
pubmed: 30528100
J Clin Endocrinol Metab. 2022 Aug 18;107(9):2644-2651
pubmed: 35665810
Kidney Int Suppl. 1997 Mar;58:S2-7
pubmed: 9067934
Curr Diab Rep. 2008 Apr;8(2):87-93
pubmed: 18445349
Lancet Diabetes Endocrinol. 2020 Jun;8(6):470-472
pubmed: 32723484
Diabetes Metab Res Rev. 2022 Mar;38(3):e3500
pubmed: 34611978
Immunotargets Ther. 2014 Dec 16;4:1-11
pubmed: 27471707
Immunotherapy. 2017 Jun;9(8):619-621
pubmed: 28653568
Cytokine. 2015 Jul;74(1):27-34
pubmed: 25481648
Front Immunol. 2017 Mar 17;8:292
pubmed: 28367149
Clin Immunol. 2017 Mar;176:114-121
pubmed: 28131926
Infect Immun. 2013 Jul;81(7):2584-91
pubmed: 23649091
Vaccine. 2014 Jul 16;32(33):4206-13
pubmed: 24837503
Lancet Diabetes Endocrinol. 2019 Jan;7(1):52-64
pubmed: 30528099
J Immunother. 2009 Feb-Mar;32(2):118-28
pubmed: 19238010
Front Immunol. 2022 Jan 12;12:797172
pubmed: 35095874
Adv Exp Med Biol. 2016;941:1-19
pubmed: 27734406
Nat Rev Immunol. 2008 Apr;8(4):247-58
pubmed: 18323851
Cytokine Growth Factor Rev. 2016 Aug;30:29-37
pubmed: 27072069
Trends Immunol. 2006 Apr;27(4):183-7
pubmed: 16527542
Int Immunol. 2009 Mar;21(3):269-82
pubmed: 19174473
Front Immunol. 2020 Oct 09;11:564921
pubmed: 33162978
Clin Immunol. 2009 May;131(2):260-70
pubmed: 19171501
Diabetes Care. 2018 Sep;41(9):1917-1925
pubmed: 30012675
Acta Diabetol. 2022 May;59(5):687-696
pubmed: 35098372
N Engl J Med. 2008 Oct 30;359(18):1909-20
pubmed: 18843118
Int Arch Allergy Immunol. 2009;150(1):59-65
pubmed: 19339803
Diabetologia. 2009 Jan;52(1):175-6
pubmed: 19005640
Annu Rev Immunol. 2003;21:425-56
pubmed: 12615888
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
J Immunol. 2009 Jun 15;182(12):8047-55
pubmed: 19494330
Diabetes. 2016 Dec;65(12):3765-3775
pubmed: 27669730
N Engl J Med. 2020 Nov 19;383(21):2007-2017
pubmed: 33207093
N Engl J Med. 2012 Feb 2;366(5):433-42
pubmed: 22296077
Diabetes Metab Res Rev. 2010 Oct;26(7):559-68
pubmed: 20830731
N Engl J Med. 2009 Nov 26;361(22):2143-52
pubmed: 19940299
Diabetes Care. 2017 Sep;40(9):1194-1202
pubmed: 28646072
Diabetologia. 2020 Oct;63(10):2177-2181
pubmed: 32754804
J Immunol. 1999 Jul 1;163(1):525-32
pubmed: 10384157
N Engl J Med. 2002 May 30;346(22):1692-8
pubmed: 12037148
Lancet. 2011 Aug 6;378(9790):487-97
pubmed: 21719095
Immunity. 2019 Apr 16;50(4):796-811
pubmed: 30995500
Diabetes Care. 2020 Jan;43(1):5-12
pubmed: 31753960
Autoimmunity. 2013 Nov;46(7):409-18
pubmed: 23786272
Nat Med. 2007 Jul;13(7):843-50
pubmed: 17558415
Cell Death Differ. 2013 Dec;20(12):1731-41
pubmed: 24076588
Anticancer Res. 2017 Mar;37(3):963-967
pubmed: 28314253
Blood. 2012 Dec 6;120(24):4882-91
pubmed: 23012326
Diabetes Care. 2013 Nov;36(11):3418-24
pubmed: 23863909
PLoS One. 2015 Dec 04;10(12):e0142976
pubmed: 26636339
Cytokine Growth Factor Rev. 1998 Mar;9(1):25-35
pubmed: 9720754
Semin Immunol. 2012 Jun;24(3):198-208
pubmed: 22421572
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
J Immunol. 2001 Jan 15;166(2):1352-9
pubmed: 11145720
Diabetes Care. 2021 Jul;44(7):1604-1612
pubmed: 34021020
J Clin Invest. 2015 Aug 3;125(8):3285-96
pubmed: 26193635
Front Immunol. 2022 Nov 23;13:1054968
pubmed: 36505460